HI HB1667

Defines "clinical laboratory director" to include physicians, licensed clinical laboratory scientists, and pharmacists serving as directors of laboratories performing only Clinical Laboratory Improvement Amendments (CLIA) waived tests.

Amends the definition of "practice of pharmacy" to allow pharmacists to order and perform CLIA waived tests, including FDA-approved or FDA-authorized tests classified as waived under CLIA (42 U.S.C. 263a), with appropriate training from ACPE-approved programs.

Prohibits pharmacists from performing tests requiring vaginal swab, venipuncture, or seminal fluid collection when performing CLIA waived tests.

Eliminates the requirement for pharmacies performing CLIA waived tests to have a clinical laboratory director sign off on applications, allowing the pharmacist-in-charge to sign instead.

Takes effect on July 1, 2060.